Lercanidipine: A long-acting dihydropyridine calcium channel blocker for treatment of hypertension

News
Article

Lercanidipine is currently under FDA review for the management of hypertension. In comparative clinical trials, lercanidipine has shown antihypertensive efficacy comparable to that of slow-release nifedipine, amlodipine, nitrendipine, verapamil, captopril, and atenolol. Its side effect profile is similar or superior to these agents. This Focus article reviews those trials as well as lercanidipine?s pharmacologic properties and addresses the agent?s potential role in patients with comorbid conditions.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.